Is BeOne Medicines AG (ONC) a Buy, Sell, or Hold?
BeOne Medicines AG
NASDAQ:ONC
$306.56 USD
$2.6 (0.86%)
- Volume
- 0
- Average Volume
- 262.11K
- Market Capitalization
- $32.76B
- P/E Ratio
- 4.94
- Dividend Yield
- 0.00%
- Price Target
- $400.00
- Year High
- $385.22
- Year Low
- $253.95
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.64
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | John V. Oyler |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ONC |
| CUSIP | 07725L102 |
| CIK | 0001651308 |
| Web | https://beonemedicines.com |
| Phone | 345-949-4123 |
| Currency | USD |
| Employees | 12000 |
| Country | CH |
Liquidity
| Debt-to-Equity Ratio | 0.43 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.64 |
| Quick Ratio | 3.27 |
| Cash Ratio | 2.67 |
Sales & Book Value
| Annual Sales | $5.34B |
| Price / Sales | 7.20 |
| Cash Flow | 0.76 |
| Price / Cash Flow | 37.66 |
| Price / Book | 11.98 |
Price Target and Rating
| Average Stock Price Forecast | $400.00 |
| High Stock Price Forecast | $451.00 |
| Low Stock Price Forecast | $340.00 |
| Forecast Upside/Downside | -23.36% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $32.11 |
| Trailing P/E Ratio | 4.94 |
| PEG Ratio | 0.01 |
| P/E Growth | 0.01 |
| Net Income | $286.93M |
| Net Margin | 8.93% |
| Pretax Margin | 11.42% |
| Return on Equity | 12.10% |
| Return on Assets | 6.00% |
Financials Score
| AltmanZ Score | 5.45 |
| Piotroski Score | 7.00 |
| Working Capital | 4.79B |
| Total Assets | 8.55B |
| Ebit | 751.8M |
| Market Cap | 32.52B |
| Total Liabilities | 3.79B |
Poll Results
About BeOne Medicines AG (NASDAQ:ONC) Stock
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric d ... egradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
2026-06-30 06:00:00
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibito.
2026-06-12 06:00:00
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton's tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic.
2026-06-11 07:24:00
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibr.
2026-06-08 13:08:29
BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?
2026-06-05 13:00:31
BeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
2026-06-02 07:21:53
BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO Transcript
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
2026-06-02 02:09:49
BeOne Medicines NASDAQ: ONC used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company said are moving toward registrational development.
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
2026-06-01 06:34:55
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines' Tevimbra immunotherapy.
Frequently Asked Questions
-
What is the current BeOne Medicines AG (ONC) stock price?
-
BeOne Medicines AG(NASDAQ:ONC) stock price is $306.56 in the last trading session. During the trading session, ONC stock reached the peak price of $385.22 while $253.948 was the lowest point it dropped to. The percentage change in ONC stock occurred in the recent session was 0.86% while the dollar amount for the price change in ONC stock was $2.6.
-
ONC's industry and sector of operation?
-
The NASDAQ listed ONC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ONC?
-
John V. Oyler | Co-Founder, Executive Chairman & Chief Executive Officer
Xiang Guo | Senior Vice President of Global Statistics & Data Science
Aaron Rosenberg | Chief Financial Officer
Kyu-Sung Lee | Senior VP and Global Head of Technical Operations & Manufacturing
Luo Lusong | Head of External Innovation & Senior VP -
How many employees does ONC have?
-
Number of ONC employees currently stands at 12000. ONC operates from 94 Aeschengraben 27, Basel, PA 4051, CH.
-
Link for ONC official website?
-
Official Website of ONC is: https://beonemedicines.com
-
How do I contact ONC?
-
ONC could be contacted at phone #345-949-4123 and can also be accessed through its website. ONC operates from 94 Aeschengraben 27, Basel, PA 4051, CH.
-
How many shares of ONC are traded daily?
-
The average number of ONC shares traded daily for last 3 months was 262.11K.
-
What is the market cap of ONC currently?
-
The market value of ONC currently stands at $32.76B with its latest stock price at $306.56